<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-06-21">21 June 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">G</forename><surname>Curigliano</surname></persName>
							<email>giuseppe.curigliano@ieo.it</email>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Breast Cancer Program</orgName>
								<orgName type="institution" key="instit2">Istituto Europeo di Oncologia</orgName>
								<address>
									<settlement>Milano</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Burstein</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Breast Oncology Center</orgName>
								<orgName type="department" key="dep2">Dana-Farber Cancer Institute</orgName>
								<orgName type="institution">Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Winer</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Breast Oncology Center</orgName>
								<orgName type="department" key="dep2">Dana-Farber Cancer Institute</orgName>
								<orgName type="institution">Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Gnant</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Surgery</orgName>
								<orgName type="department" key="dep2">Comprehensive Cancer Center Vienna</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Dubsky</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Surgery</orgName>
								<orgName type="department" key="dep2">Comprehensive Cancer Center Vienna</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Klinik St. Anna</orgName>
								<address>
									<settlement>Luzern</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">German Breast Group</orgName>
								<address>
									<settlement>Neu-Isenburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Colleoni</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Breast Cancer Program</orgName>
								<orgName type="institution" key="instit2">Istituto Europeo di Oncologia</orgName>
								<address>
									<settlement>Milano</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Regan</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Biostatistics and Computational Biology</orgName>
								<orgName type="department" key="dep2">Dana-Farber Cancer Institute</orgName>
								<orgName type="institution">Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Piccart-Gebhart</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Medical Oncology</orgName>
								<orgName type="department" key="dep2">Institut Jules Bordet</orgName>
								<orgName type="institution">UniversitO ˜Libre de Bruxelles</orgName>
								<address>
									<settlement>Brussels</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H.-J</forename><surname>Senn</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Tumor and Breast Center ZeTuP</orgName>
								<address>
									<settlement>St. Gallen</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Thu ¨rlimann</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Breast Center</orgName>
								<orgName type="institution">Kantonsspital St</orgName>
								<address>
									<settlement>Gallen, St. Gallen</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Andre</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">Institut de Cance ´rologie Gustave Roussy</orgName>
								<address>
									<settlement>Villejuif</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Baselga</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Memorial Sloan Kettering Cancer Center</orgName>
								<address>
									<region>New York</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Bergh</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">Karolinska Institute and University Hospital</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Bonnefoi</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">University of Bordeaux</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Brucker</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">Universit€ ats-Frauenklinik Tu ¨bingen</orgName>
								<address>
									<addrLine>Tu ¨bingen</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Cardoso</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution">Champalimaud Cancer Centre</orgName>
								<address>
									<settlement>Lisbon</settlement>
									<country key="PT">Portugal</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Carey</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Lineberger Comprehensive Cancer Center</orgName>
								<orgName type="institution">University of North Carolina</orgName>
								<address>
									<settlement>Chapel Hill</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Ciruelos</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution">Hospital Universitario</orgName>
								<address>
									<addrLine>12 de Octubre</addrLine>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Cuzick</surname></persName>
							<affiliation key="aff17">
								<orgName type="laboratory">Centre for Cancer Prevention</orgName>
								<orgName type="institution" key="instit1">Wolfson Institute of Preventive Medicine</orgName>
								<orgName type="institution" key="instit2">Mary University of London</orgName>
								<address>
									<settlement>London</settlement>
									<region>Queen</region>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Denkert</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Institut fu ¨r Pathologie</orgName>
								<address>
									<settlement>Charite Úniversit€ atsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><forename type="middle">Di</forename><surname>Leo</surname></persName>
							<affiliation key="aff19">
								<orgName type="institution">Azienda Usl Toscana Centro</orgName>
								<address>
									<settlement>Prato</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Ejlertsen</surname></persName>
							<affiliation key="aff20">
								<orgName type="institution">Rigshospitalet</orgName>
								<address>
									<settlement>Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Francis</surname></persName>
							<affiliation key="aff21">
								<orgName type="institution">Peter McCallum Cancer Centre</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">V</forename><surname>Galimberti</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Breast Cancer Program</orgName>
								<orgName type="institution" key="instit2">Istituto Europeo di Oncologia</orgName>
								<address>
									<settlement>Milano</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Garber</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Breast Oncology Center</orgName>
								<orgName type="department" key="dep2">Dana-Farber Cancer Institute</orgName>
								<orgName type="institution">Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Gulluoglu</surname></persName>
							<affiliation key="aff22">
								<orgName type="institution">Marmara University School of Medicine</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Goodwin</surname></persName>
							<affiliation key="aff23">
								<orgName type="institution" key="instit1">University of Toronto</orgName>
								<orgName type="institution" key="instit2">Mount Sinai Hospital</orgName>
								<address>
									<settlement>Toronto</settlement>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">N</forename><surname>Harbeck</surname></persName>
							<affiliation key="aff24">
								<orgName type="institution">University of Munich</orgName>
								<address>
									<addrLine>Mu ¨nchen</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Hayes</surname></persName>
							<affiliation key="aff25">
								<orgName type="department">Comprehensive Cancer Center</orgName>
								<orgName type="institution">University of Michigan</orgName>
								<address>
									<settlement>Ann-Arbor</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C.-S</forename><surname>Huang</surname></persName>
							<affiliation key="aff26">
								<orgName type="institution">National Taiwan University Hospital</orgName>
								<address>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Huober</surname></persName>
							<affiliation key="aff27">
								<orgName type="institution">University of Ulm</orgName>
								<address>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Khaled</surname></persName>
							<affiliation key="aff28">
								<orgName type="institution" key="instit1">The National Cancer Institute</orgName>
								<orgName type="institution" key="instit2">Cairo University</orgName>
								<address>
									<settlement>Cairo</settlement>
									<country key="EG">Egypt</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Jassem</surname></persName>
							<affiliation key="aff29">
								<orgName type="institution">Medical University of Gdansk</orgName>
								<address>
									<settlement>Gdansk</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Z</forename><surname>Jiang</surname></persName>
							<affiliation key="aff30">
								<orgName type="institution">Hospital Affiliated to Military Medical Science</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Karlsson</surname></persName>
							<affiliation key="aff31">
								<orgName type="department">Institute of Clinical Sciences</orgName>
								<orgName type="institution" key="instit1">Sahlgrenska Academy</orgName>
								<orgName type="institution" key="instit2">Sahlgrensky University Hospital</orgName>
								<address>
									<settlement>Gothenburg</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Morrow</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Memorial Sloan Kettering Cancer Center</orgName>
								<address>
									<region>New York</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Orecchia</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Breast Cancer Program</orgName>
								<orgName type="institution" key="instit2">Istituto Europeo di Oncologia</orgName>
								<address>
									<settlement>Milano</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Osborne</surname></persName>
							<affiliation key="aff32">
								<orgName type="institution">Baylor College of Medicine</orgName>
								<address>
									<settlement>Houston</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">O</forename><surname>Pagani</surname></persName>
							<affiliation key="aff33">
								<orgName type="department">Institute of Oncology Southern Switzerland</orgName>
								<orgName type="institution">Ospedale San Giovanni</orgName>
								<address>
									<settlement>Bellinzona</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Partridge</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Breast Oncology Center</orgName>
								<orgName type="department" key="dep2">Dana-Farber Cancer Institute</orgName>
								<orgName type="institution">Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Pritchard</surname></persName>
							<affiliation key="aff34">
								<orgName type="department">Sunnybrook Odette Cancer Center</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<settlement>Toronto</settlement>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Ro</surname></persName>
							<affiliation key="aff35">
								<orgName type="institution">National Cancer Center</orgName>
								<address>
									<addrLine>Ilsandong-gu, Goyang-si</addrLine>
									<settlement>Gyeonggi-do</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><forename type="middle">J T</forename><surname>Rutgers</surname></persName>
							<affiliation key="aff36">
								<orgName type="institution">Netherlands Cancer Institute</orgName>
							</affiliation>
							<affiliation key="aff37">
								<orgName type="institution">Antoni van Leeuwenhoek Hospital</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Sedlmayer</surname></persName>
							<affiliation key="aff38">
								<orgName type="institution" key="instit1">LKH Salzburg</orgName>
								<orgName type="institution" key="instit2">Paracelsus Medical University Clinics</orgName>
								<address>
									<settlement>Salzburg</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">V</forename><surname>Semiglazov</surname></persName>
							<affiliation key="aff39">
								<orgName type="institution">N.N. Petrov Research Institute of Oncology</orgName>
								<address>
									<settlement>St. Petersburg</settlement>
								</address>
							</affiliation>
							<affiliation key="aff40">
								<orgName type="institution">Russian Federation</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Z</forename><surname>Shao</surname></persName>
							<affiliation key="aff41">
								<orgName type="institution">Fudan University Cancer Hospital</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">I</forename><surname>Smith</surname></persName>
							<affiliation key="aff42">
								<orgName type="institution">The Royal Marsden</orgName>
								<address>
									<settlement>Sutton</settlement>
									<region>Surrey</region>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Toi</surname></persName>
							<affiliation key="aff43">
								<orgName type="institution">Graduate School of Medicine Kyoto University</orgName>
								<address>
									<addrLine>Sakyo-ku</addrLine>
									<settlement>Kyoto City</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Tutt</surname></persName>
							<affiliation key="aff44">
								<orgName type="department">Breast Cancer Now Research Centre</orgName>
								<orgName type="institution">The Institute of Cancer Research</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Viale</surname></persName>
							<affiliation key="aff45">
								<orgName type="institution">University of Milan</orgName>
								<address>
									<settlement>Milan</settlement>
								</address>
							</affiliation>
							<affiliation key="aff46">
								<orgName type="institution">Istituto Europeo di Oncologia</orgName>
								<address>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Watanabe</surname></persName>
							<affiliation key="aff47">
								<orgName type="institution">Hamamatsu Oncology Center</orgName>
								<address>
									<settlement>Hamamatsu</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Whelan</surname></persName>
							<affiliation key="aff48">
								<orgName type="institution">McMaster University</orgName>
								<address>
									<settlement>Hamilton</settlement>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Xu</surname></persName>
							<affiliation key="aff49">
								<orgName type="institution">National Cancer Center</orgName>
								<address>
									<settlement>Chaoyang District, Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Prof</roleName><forename type="middle">Giuseppe</forename><surname>Curigliano</surname></persName>
						</author>
						<author>
							<affiliation key="aff50">
								<orgName type="department">Division of Early Drug Development for Innovative Therapies</orgName>
								<orgName type="institution">Istituto Europeo di Oncologia</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milano</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-06-21">21 June 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">925D5DC8A64E5CC9AD43FA481F6E25C1</idno>
					<idno type="DOI">10.1093/annonc/mdx308</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:08+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>St Gallen Consensus</term>
					<term>early breast cancer</term>
					<term>radiation therapy</term>
					<term>surgery</term>
					<term>systemic adjuvant therapies</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer.</s><s>Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology.</s><s>The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer.</s><s>The Panel favored escalating radiation therapy with regional nodal irradiation in high-risk patients, while encouraging omission of boost in low-risk patients.</s><s>The Panel endorsed gene expression signatures that permit avoidance of chemotherapy in many patients with ER positive breast cancer.</s><s>For women with higher risk tumors, the Panel escalated recommendations for adjuvant endocrine treatment to include ovarian suppression in premenopausal women, and extended therapy for postmenopausal women.</s><s>However, low-risk patients can avoid these treatments.</s><s>Finally, the Panel recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence.</s><s>The Panel recognized that recommendations are not intended for all patients, but rather to address the clinical needs of the majority of common presentations.</s><s>Individualization of adjuvant therapy means adjusting to the tumor characteristics, patient comorbidities and preferences, and managing constraints of treatment cost and access that may affect care in both the developed and developing world.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>The 15th St. Gallen International Breast Cancer Consensus Conference was held in March 2017 in Vienna, Austria.</s><s>This meeting is a global, multidisciplinary conference with representatives from 160 nations and every continent.</s><s>The highlight of the conference is the consensus panel, in which 52 panelists review and discuss specific areas of treatment with a focus on controversies in the management of early-stage breast cancer.</s><s>The goal of this consensus process is to articulate important themes in management, and to provide guidance to clinicians around the world on how to think about and care for women with early-stage breast cancer.</s><s>It is acknowledged that not all countries have equal access to therapeutic and diagnostic resources.</s><s>In light of that, the Panel attempts to review less costly alternatives when they may be appropriately utilized (Table <ref type="table">1</ref>).</s></p><p><s>The theme for this year's conference was to focus on areas of 'escalation' or 'de-escalation'.</s><s>That is-to identify areas where optimal care may be achieved with 'less' or 'more' treatment.</s><s>The Panelists believe very strongly in the importance of evidence-based clinical care.</s><s>At the same time, they recognize that data from randomized phase III studies are not always relevant to specific situations and may not be available to resolve important clinical decisions.</s><s>The needs of a specific patient may be better defined through consideration of subset analyses or other individualized approaches to care.</s><s>In these instances, the Panel voiced its expert judgment in order to assist in the care of individual women as best they could.</s><s>The panel endorses treatment in well-designed clinical trials allowing access to best available care.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ductal carcinoma in situ</head><p><s>Breast conserving surgery followed by radiation therapy remains the standard of care for ductal carcinoma in situ (DCIS) <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref> assuming adequate margins can be obtained.</s><s>The majority of panel endorsed recent Surgical Society of Oncology (SSO), American Society of Clinical Oncology (ASCO) and American Society for Radiation Oncology (ASTRO) guidelines that recommended that a margin !2 mm is sufficient to avoid re-excision <ref type="bibr" target="#b2">[3]</ref>.</s><s>A substantial minority of the panel would accept narrower margins in individual cases, including 'no ink on DCIS'.</s><s>The Panel acknowledged the recent trials showing that either aromatase inhibitors (AIs) or tamoxifen can be an effective adjuvant treatment options to lower the risk of recurrent DCIS <ref type="bibr" target="#b3">[4,</ref><ref type="bibr">5]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary surgery for early breast cancer</head><p><s>The Panel discussed whether women with multifocal (multiple areas of tumor in one quadrant) or multicentric (multiple areas of tumor affecting more than one quadrant) are candidates for breast conservation.</s><s>The Panel strongly endorsed breast conservation for both multifocal and multicentric disease provided that surgical margins are negative, that radiotherapy is anticipated, and that the surgical resection would achieve adequate cosmesis.</s><s>The Panel reiterated the 'no ink on tumor' rule for surgical margins of invasive breast cancer, and recommended this standard regardless of tumor biology or subtype <ref type="bibr" target="#b5">[6]</ref>.</s></p><p><s>A meta-analysis of single-center experiences suggests very low risk of local-regional recurrence following nipple-sparing mastectomy <ref type="bibr" target="#b6">[7]</ref>.</s><s>Based on these observations, the Panel endorsed nipple-sparing mastectomy as an appropriate surgical option.</s><s>Additionally, the Panel specifically endorsed nipple-sparing mastectomy as an option for breast surgery in women with known hereditary BRCA1/2 mutations provided that there was careful review of the retro-areolar tissue by pathology with no evidence for tumor in that region.</s></p><p><s>Based on the American College of Surgeons Oncology Group (ACOSOG) Z-11 trial, it has become standard to avoid axillary dissection in women with 1 or 2 positive sentinel lymph nodes who have had breast conservation and will be receiving whole breast radiation and adjuvant systemic therapy, regardless of tumor biology <ref type="bibr" target="#b7">[8]</ref>.</s><s>The Panel believed that either standard 'tangents' or 'high tangents' were appropriate radiation fields for such cases, and had no specific preference.</s></p><p><s>The Panel discussed how this experience relates to women who have had mastectomy.</s><s>The Panel recommended additional therapy to the axilla in women who had had mastectomy and sentinel</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 1. Research recent findings and clinical implications</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Field of treatment Findings and implications</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Genetics</head><p><s>Multi-gene panel testing for hereditary breast cancer becomes widespread, frequently identifying deleterious mutations in women with family history but negative BRCA1/2 testing, and also introducing substantial numbers of variants of unknown significance <ref type="bibr" target="#b46">[46]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Surgery of ductal carcinoma in situ</head><p><s>Meta-analysis and expert panel recommends !2 mm margins as optimal for women receiving breast conserving surgery and radiation therapy for DCIS <ref type="bibr" target="#b2">[3]</ref>.</s><s>Systemic therapy of ductal carcinoma in situ (DCIS)</s></p><p><s>Randomized trials comparing the aromatase inhibitor (AI), anastrozole, against tamoxifen as treatment of estrogen receptor (ER) positive DCIS showed that the AI was at least as effective as tamoxifen, with differences in side-effect profiles <ref type="bibr" target="#b3">[4,</ref><ref type="bibr">5]</ref>.</s><s>Surgery of the axilla after neoadjuvant therapy</s></p><p><s>Prospective trials of sentinel node vs axillary node dissection for women with node-positive breast cancer following neoadjuvant chemotherapy showed that false-negative rates for sentinel lymph node (SLN) were in excess of 10%.</s><s>However, the SLN mapping may be acceptable in selected cohorts <ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Partial breast irradiation</head><p><s>In a randomized trial of low-risk patients with early breast cancer who received breast conserving surgery, accelerated partial breast irradiation was not inferior to standard whole breast irradiation <ref type="bibr" target="#b47">[47]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Regional nodal irradiation</head><p><s>Randomized trials demonstrate reduced local-regional and distant metastatic recurrence, with emerging survival advantage, for regional nodal irradiation to supraclavicular, axillary and internal mammary lymph nodes when treating high-risk breast cancers following breast surgery.</s><s>While reducing risk of recurrence, regional nodal irradiation was associated with greater risk of toxicity and may complicate reconstructive surgery <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b20">21]</ref>.</s><s>Neoadjuvant therapy: Chemotherapy</s></p><p><s>The inclusion of carboplatin with anthracycline-and taxane-based chemotherapy improved the rate of pathologic complete response (pCR) in triple negative breast cancer (TNBC) and translated into disease-free survival benefit though the role for such treatment when patients additionally receive standard alkylator therapy is less clear <ref type="bibr" target="#b49">[48]</ref>.</s><s>In an adaptive randomized trial, the addition of carboplatin and the PARP inhibitor, veliparib, improved the rate of pCR in TNBC <ref type="bibr" target="#b50">[49]</ref>.</s><s>There were inconsistent findings for the use of nab-paclitaxel instead of paclitaxel as neoadjuvant chemotherapy <ref type="bibr" target="#b51">[50,</ref><ref type="bibr" target="#b52">51]</ref>.</s><s>Neoadjuvant therapy-HER2 targeted therapy</s></p><p><s>Long-term follow-up of NeoSphere trial suggests disease-free survival advantage parallels increased rate of pCR with pertuzumab-and trastuzumab-based therapy <ref type="bibr" target="#b53">[52]</ref>.</s><s>The antibody-drug conjugate, ado-trastuzumab emtansine paired with pertuzumab was less effective at achieving pCR than the chemotherapy-trastuzumab-pertuzumab TCHP <ref type="bibr" target="#b54">[53]</ref>.</s><s>An adaptive randomized trial suggested that the dual tyrosine kinase inhibitor neratinib, might improve rates of pCR compared with trastuzumab-based regimens though this awaits confirmation <ref type="bibr" target="#b55">[54]</ref>.</s><s>Neoadjuvant therapyendocrine therapy.</s></p><p><s>The addition of the cyclin-dependent kinase (CDK) 4/6 inhibitors to aromatase inhibitor treatment dramatically suppresses tumor cell proliferation <ref type="bibr" target="#b56">[55]</ref><ref type="bibr" target="#b57">[56]</ref><ref type="bibr" target="#b58">[57]</ref>.</s><s>Among women with low genomic scores, neoadjuvant endocrine therapy is associated with high rates of clinical response <ref type="bibr" target="#b59">[58]</ref>.</s><s>Post-neoadjuvant therapy-clinical trials</s></p><p><s>Ongoing trials are evaluating post-neoadjuvant therapy for patients who have residual cancer.</s><s>Agents under investigation include CDK 4/6 inhibitors, poly ADP ribose polymerase (PARP) inhibitors, platinum agents, ado-trastuzumab emtansine, immunotherapy agents, and others.</s><s>Adjuvant capecitabine may reduce recurrence in women with residual cancer after neoadjuvant chemotherapy <ref type="bibr" target="#b41">[42]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjuvant therapy-Chemotherapy</head><p><s>The ABC trials suggest that inclusion of anthracylines in addition to taxanes and alkylator chemotherapy remains valuable for triple-negative and stage II/III ER positive cancers treated with adjuvant chemotherapy <ref type="bibr" target="#b60">[59]</ref>.</s><s>The addition of bevacizumab to chemotherapy did not improve long-term outcomes for triple-negative breast cancer <ref type="bibr" target="#b61">[60]</ref>.</s><s>Adjuvant capecitabine may reduce recurrence in TNBC when added to anthracycline-and taxane-based chemotherapy <ref type="bibr" target="#b62">[61]</ref>, and may reduce recurrence in women with residual cancer after neoadjuvant chemotherapy <ref type="bibr" target="#b41">[42]</ref>.</s><s>'Dose-dense' chemotherapy scheduling is validated for reducing cancer recurrence while 5-fluorouracil was shown to not affect recurrence risk <ref type="bibr" target="#b63">[62,</ref><ref type="bibr" target="#b64">63]</ref>.</s><s>Adjuvant therapy-HER2 targeted therapy Despite multiple trials demonstrating enhanced rates of pCR with the addition of lapatinib to trastuzumab-based neoadjuvant chemotherapy, long-term findings from the ALTTO study do not suggest reduced recurrence risk with adjuvant lapatinib <ref type="bibr" target="#b65">[64]</ref>.</s><s>The ExtaNet study suggests that extended anti-HER2 treatment with the dual tyrosine kinase inhibitor, neratinib, reduces recurrence risk, particularly in ER positive, HER2 positive tumors but is associated with significant rates of diarrhea <ref type="bibr" target="#b66">[65]</ref>.</s><s>Trastuzumab reduced risk even in small, sub-centimeter, node-negative breast cancers <ref type="bibr" target="#b67">[66]</ref>.</s><s>Paclitaxel and trastuzumab is an effective regimen for stage I breast cancers with low rates of recurrence <ref type="bibr" target="#b68">[67]</ref>.</s><s>Dual blockade with pertuzumab and trastuzumab improves outcome among patients who are at higher risk for relapse because of lymph-node involvement or hormone-receptor negativity <ref type="bibr" target="#b91">[90]</ref>.</s><s>Adjuvant therapy-endocrine therapy</s></p><p><s>In premenopausal women with ER positive breast cancer, ovarian suppression reduces recurrence in high-risk tumors but is associated with more menopausal symptoms <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b69">68]</ref>.</s><s>In postmenopausal women, multiple trials have studied extended endocrine therapy with an aromatase inhibitor and have shown reduced rates of breast cancer events, including distant recurrence and contralateral breast cancers though the absolute benefit is modest <ref type="bibr" target="#b37">[38,</ref><ref type="bibr" target="#b40">41]</ref>.</s><s>Randomized trials show equivalence between anastrozole and letrozole as adjuvant treatment <ref type="bibr" target="#b70">[69]</ref>.</s><s>Gene expression profiling for early-stage breast cancer: prospective studies</s></p><p><s>In the MINDACT trial, a 70-gene signature paired with clinical risk criteria identified patients with breast cancer who did not derive substantial benefit from adjuvant chemotherapy <ref type="bibr" target="#b22">[23]</ref>.</s><s>In the TAILORx and West German Plan B trials, a very low 21gene recurrence score identified a cohort of patients with ER positive breast cancer and an excellent prognosis with endocrine therapy alone <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b24">25]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Continued</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Special article</head><p><s>node biopsy with macro-metastases affecting one or two lymph nodes.</s><s>The Panel believed that either postsurgical radiation therapy or axillary dissection would be appropriate for such patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Breast surgery following neoadjuvant therapy</head><p><s>Neoadjuvant therapy serves two main goals.</s><s>It provides effective systemic treatment (equivalent to adjuvant therapy) to prevent cancer recurrence, and allows de-escalating surgery for many women with larger tumors and/or axillary nodal involvement.</s><s>The Panel addressed the question: 'Should the entire area of the original primary be resected after neoadjuvant therapy or should the resection include only the residual area of tumor?', and the panel deliberated about the appropriate surgical margins following neoadjuvant treatment <ref type="bibr" target="#b8">[9]</ref>.</s><s>The Panel recommended that the extent of residual tumor guide the extent of breast surgery, and that full resection of the initial tumor bed was not necessary.</s><s>In general, the Panel favored the 'no ink on tumor' standard for surgical margins following neoadjuvant therapy.</s><s>However, in cases of multifocal residual disease and/or cases of 'scattered' residual disease, many panelists expressed an expert opinion to favor more 'generous' margins.</s><s>No single standard of care exists and the multidisciplinary team caring for the patient needs to exercise appropriate clinical judgment.</s><s>Similarly, the Panel agreed that nipple-sparing mastectomy was an option for patients following neoadjuvant treatment provided the retro-areolar region lacked tumor involvement <ref type="bibr" target="#b9">[10]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Axillary surgery following neoadjuvant therapy</head><p><s>The Panel deliberated on appropriate axillary surgery following neoadjuvant chemotherapy.</s><s>In a woman who presented with a clinically negative axilla and who received neoadjuvant treatment, the Panel strongly believed sentinel node biopsy to be appropriate and favored the biopsy be carried out after neoadjuvant treatment.</s></p><p><s>There was more controversy regarding sentinel node surgery for women who presented with a clinically positive axilla, and had a clinical response with down staging to a clinically negative axilla.</s><s>The Panel believed sentinel node biopsy, as opposed to axillary dissection, to be adequate if at least three or more negative sentinel nodes were detected and examined <ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref>.</s><s>Because of concerns for false-negative results with limited sampling, sentinel node surgery was generally considered not adequate if only one or two negative sentinel nodes were identified.</s><s>The Panel recommended that patients with a clinically positive axilla or with macrometastases identified in sentinel nodes after neoadjuvant therapy undergo completion axillary dissection <ref type="bibr" target="#b14">[15]</ref>.</s><s>The Panel was split on whether residual micro-metastatic lymph node involvement warranted completion dissection after neoadjuvant therapy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Radiation therapy after breast surgery</head><p><s>Because of high levels of evidence for safety and long-term efficacy, the Panel believed that hypo-fractionated treatment was an appropriate standard for the majority of patients, particularly those over age 50 years, and that this represented an opportunity for Table <ref type="table">1</ref>.</s><s>Continued</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Field of treatment Findings and implications</head><p><s>Bone modifying therapy A meta-analysis of adjuvant bisphosphonate therapy trials demonstrated reduced risk of recurrence in postmenopausal women <ref type="bibr" target="#b42">[43]</ref>.</s><s>Denosumab can reduce the risk of bone fracture and may reduce recurrence risk in postmenopausal women <ref type="bibr" target="#b44">[44]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survivorship</head><p><s>Prospective studies suggest that scalp cooling devices may reduce the incidence of alopecia in women with early-stage breast cancer receiving non-anthracycline-based chemotherapy <ref type="bibr" target="#b71">[70,</ref><ref type="bibr" target="#b45">45]</ref>.</s><s>Interventions including exercise or duloxetine may reduce aromatase inhibitor-associated arthralgias <ref type="bibr" target="#b72">[71]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Metastatic diseaseimmunotherapy</head><p><s>Anti-programmed death-1 (PD-1)/Programmed death-ligand 1 (PD-L1) antibodies have shown activity as single-agents or in combination with taxane-based chemotherapy in TNBC <ref type="bibr" target="#b73">[72]</ref><ref type="bibr" target="#b74">[73]</ref><ref type="bibr" target="#b75">[74]</ref>.</s><s>Metastatic disease-CDK4/6 inhibitors Randomized trials have shown that adding CDK4/6 inhibitors to first-or second line endocrine therapy improves progression free survival <ref type="bibr" target="#b76">[75]</ref><ref type="bibr" target="#b77">[76]</ref><ref type="bibr" target="#b78">[77]</ref>.</s><s>Metastatic disease-HER2 directed therapy</s></p><p><s>First-line therapy with ado-trastuzumab emtansine and pertuzumab was not superior to chemotherapy and trastuzumab or ado-trastuzumab emtansine, alone <ref type="bibr" target="#b79">[78]</ref>.</s><s>Adding pertuzumab to second-line chemotherapy in patients not previously treated with pertuzumab yielded small clinical benefit <ref type="bibr" target="#b80">[79]</ref>.</s><s>In the PERTAIN trial, adding pertuzumab to first-line trastuzumab and endocrine therapy improved progression free survival <ref type="bibr" target="#b81">[80]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Molecular mechanisms of resistance to therapy</head><p><s>Activating mutations in the estrogen receptor ESR1 gene arise in 30%-40% of recurrences on AI therapy and likely account for resistance to AI treatment in those cases <ref type="bibr" target="#b82">[81]</ref>.</s><s>BRCA-associated metastatic breast cancer BRCA-mutated tumors show preferential benefit for carboplatin-based chemotherapy in palliation of metastatic disease <ref type="bibr" target="#b83">[82]</ref>.</s></p><p><s>The addition of veliparib to carboplatin and paclitaxel chemotherapy did not meaningfully improve outcomes in BRCAassociated advanced breast cancer <ref type="bibr" target="#b84">[83]</ref>.</s><s>Preliminary data from the Olympia D trial suggest that olaparib is a more effective treatment of BRCA-associated advanced breast cancer than non-platinum chemotherapy options.</s><s>Metastatic disease-phosphatidylinositol-4,5bisphosphate 3-kinase (PI3KC)</s></p><p><s>PI3K mutations are common in advanced breast cancer.</s><s>Randomized trials are evaluating the addition of PI3K inhibitors to endocrine therapy.</s><s>These agents vary in their targeting of PI3K isoforms, and the trials differ in their inclusion and assessment of tumors by PI3K mutation status.</s><s>To date, there are no clinically compelling outcomes from these studies <ref type="bibr" target="#b85">[84]</ref><ref type="bibr" target="#b86">[85]</ref><ref type="bibr" target="#b87">[86]</ref>.</s></p><p><s>There may be more activity with more alpha-selective agents in tumors with PI3K mutations.</s></p><p><s>treatment de-escalation <ref type="bibr" target="#b15">[16]</ref>.</s><s>The Panel also recognized partial breast irradiation as an option for women meeting the low-risk criteria put forward by the ASTRO/European Society for Radiotherapy and Oncology (ESTRO) guideline though acknowledged that there was less evidence for this approach <ref type="bibr" target="#b16">[17]</ref>.</s><s>For women with intermediate or higher clinical risk, the Panel preferred whole breast irradiation.</s><s>In another instance of de-escalation, the Panel believed that 'boost' could be omitted in patients aged !60, with low grade tumor features and/or favorable tumor biology who will be taking adjuvant endocrine therapy <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref>.</s><s>Two recent randomized trials have shown improved oncological outcomes in terms of disease free survival for regional nodal irradiation (RNI) for women with higher risk breast cancers <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b20">21]</ref>.</s><s>The Panel recommended RNI in patients with pN1 (one to three positive nodes) cancers and adverse clinical features including young age ( 40 years), adverse biology such as low or negative estrogen receptor (ER) expression, high grade features, and extensive lympho-vascular invasion (LVI), and all patients with four or more positive lymph nodes.</s><s>For women pN1 with lower risk features the potential benefits of RNI should be weighed against risks for toxicity, including pneumonitis and lymphedema.</s><s>The Panel recommended post-mastectomy radiation therapy (PMRT) in all patients with four or more positive lymph nodes and/or pT3 tumors.</s><s>For pN1 with lower risk features the use of PMRT should be weighed against risks for toxicity, including increased of complications following breast reconstruction.</s></p><p><s>Table <ref type="table" target="#tab_0">2</ref> summarizes treatment recommendations for locoregional therapies.</s></p><p><s>The Panel acknowledged the limited data for tailored radiation therapy based on neoadjuvant treatment response, and recommended that both baseline and post-treatment cancer stage be considered in planning whether and how to administer radiation therapy.</s><s>Finally, in the sentinel node-era, it is likely that radiation treatment decisions will need to be made with less complete staging information.</s><s>Ongoing clinical trials including the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-51 and Alliance A11202 studies will inform this decision.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Characterization of tumor biology, subtypes, and genomic signatures</head><p><s>The St. Gallen Consensus has for years led in the development of treatment tailored toward clinical and biological subsets of breast cancer.</s><s>In broad clinical terms, there are four subtypes of breast cancer that call for distinct treatment approaches: triple-negative tumors, for which chemotherapy is both effective and the only available therapy; HER2 positive tumors regardless of ER status, for which anti-HER2 therapy and chemotherapy are indicated; and two types of ER positive breast cancer, both of which are treated with endocrine therapy.</s><s>For many of these patients with hormone receptor positive disease, chemotherapy can be omitted.</s><s>ER and progesterone receptor (PR) status is determined by immunohistochemistry (IHC); human epidermal growth factor receptor (HER2) status is determined by IHC and/or in situ hybridization assays.</s><s>In addition, tumors are characterized by grade and proliferative fraction (most commonly assessed by Ki-67 immunostaining), factors that may affect the recommendation for chemotherapy in ER positive tumors (Table <ref type="table" target="#tab_1">3</ref>).</s><s>The Panel raised an issue of caution about reproducibility of IHC for Ki67 and its use to make clinical decisions, due to the variability of this assay.</s><s>If used, panelists suggested to calibrate a common scoring method in order to achieve high inter-laboratory reproducibility in Ki67 scoring on centrally stained tissue microarray slides <ref type="bibr" target="#b89">[88,</ref><ref type="bibr" target="#b90">89]</ref>.</s><s>Although these data are potentially encouraging, suggesting that it may be possible to standardize scoring of Ki67 among pathology laboratories, clinically important discrepancies persist.</s><s>The Panel recommended against routine reporting of tumor infiltrating lymphocytes for early breast cancer.</s></p><p><s>As a clinical 'short-hand', tumors are often classified as 'luminal-A like' or 'luminal-B like' based on routine pathology.</s><s>Luminal A-like tumors are typically low grade, strongly ER/PR positive, HER2 negative and have low proliferative fraction.</s><s>Luminal-B-like tumors are ER positive but may have variable degrees of ER/PR expression, are higher grade, and have higher proliferative fraction.</s><s>The Panel acknowledged that these classifications based on routine histopathology were clinically valuable, and could be used to inform adjuvant treatment decisions.</s><s>Specifically, the panel agreed that either grading or Ki-67 could be used to distinguish between the Luminal-A-and B-like (Table <ref type="table" target="#tab_1">3</ref>).</s></p><p><s>However, the panel agreed that, when available, gene expression signatures were preferable to standard pathology, when adequate reproducibility is not granted.</s><s>There was considerable discussion concerning the indication for gene expression signatures <ref type="bibr" target="#b21">[22]</ref>.</s><s>The panel agreed that there was no role in clinical low risk cases [such as pT1a/b, grade 1 (G1), ER high, N0] and similar settings where chemotherapy would not be indicated under any circumstances.</s><s>The Panel agreed that a number of gene expression signatures served as prognostic markers in the setting of adjuvant endocrine therapy in node-negative breast cancers, including the 21 gene recurrence score, the 70 gene signature, the PAM50 ROR score V R , the EpClin score V R , and the Breast Cancer Index V R .</s><s>The Panel endorsed all of these assays for guiding the decision on adjuvant chemotherapy in node-negative tumors as they all identify node-negative cases at low risk, with an excellent prognosis that would not warrant chemotherapy <ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref>.</s></p><p><s>Nodal status is a strong prognostic factor regardless of gene expression signature.</s><s>The Panel agreed that gene expression signatures offered information that can refine the prognosis for node-positive breast cancers.</s><s>However, the Panel did not uniformly endorse the use of gene expression signatures for making treatment decisions regarding adjuvant chemotherapy in nodepositive cases.</s><s>The 21-gene recurrence score and the 70-gene signature have now been evaluated in prospective studies including small numbers of node-positive cancers.</s><s>In the prospective trial (MINDACT), only patients with node-negative, or one to three positive nodes were included.</s><s>Patients with low-risk tumor scores and a limited degree of nodal involvement appear to have a good prognosis with or without chemotherapy <ref type="bibr" target="#b27">[28,</ref><ref type="bibr" target="#b28">29]</ref>.</s></p><p><s>The Panel reviewed similar data showing that some gene expression signatures appear to be prognostic for late recurrence of ER positive breast cancers after 5 years of adjuvant endocrine therapy <ref type="bibr" target="#b29">[30,</ref><ref type="bibr" target="#b30">31]</ref>.</s><s>However, the Panel did not recommend the use of gene expression signatures for choosing whether to recommend extended adjuvant endocrine treatment, as no prospective data exist and the retrospective data were not considered sufficient to justify the routine use of genomic assays in this setting.</s><s>The Panel discussed the routine indications for multigene testing in ER positive breast cancer.</s><s>The principal role is to recommend for or against adjuvant chemotherapy.</s><s>In patients who are not candidates for adjuvant chemotherapy owing to comorbid health conditions or tumor stage/risk, or in patients who 'obviously' need adjuvant chemotherapy, typically including stage III breast cancer, there is no routine need for genomic tests.</s><s>In general, the zone 'in between' is where genomic assays may be most valuable.</s><s>These would often be patients with tumors between 1 and 3 cm, with zero to two or three positive lymph nodes, and intermediate proliferative fraction.</s><s>Multigene assay should not be the only factor considered in making a decision to proceed or to avoid chemotherapy.</s><s>This broad description is intended to give guidance to clinicians and was not intended to deny access of patients with other clinical presentation where the refined prognosis available by genomic assay might reasonably inform the adjuvant chemotherapy decision.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Special article</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjuvant endocrine therapy: premenopausal women</head><p><s>Tamoxifen is the historical standard adjuvant endocrine therapy for premenopausal women.</s><s>The Panel reviewed data from recent trials of adjuvant ovarian function suppression (OFS) that demonstrated that OFS can lower the risk of breast cancer recurrence in higher risk cancers <ref type="bibr" target="#b31">[32]</ref>.</s><s>The Panel identified age 35 and/or involvement of 4 or more lymph nodes as factors arguing for inclusion of OFS.</s><s>In general, based on published reports, women with sufficient tumor risk so as to warrant chemotherapy may wish to consider OFS.</s><s>The Panel believed OFS could be paired with either tamoxifen or an AI (Table <ref type="table" target="#tab_2">4</ref>) <ref type="bibr" target="#b32">[33,</ref><ref type="bibr" target="#b33">34]</ref>.</s><s>Chemotherapy may cause transient or permanent menopause in younger women.</s><s>The Panel urged caution when interpreting laboratory assays of pituitary-ovarian function such as estradiol, folliclestimulating hormone, or luteinizing hormone levels in women treated with chemotherapy, and encouraged use of gonadotropin-releasing hormone (GnRH) agonist therapy to achieve OFS when there was any clinical ambiguity regarding menstrual function, particularly if an AI is administered (Table <ref type="table" target="#tab_2">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjuvant endocrine therapy: postmenopausal women</head><p><s>A vast literature supports the use of tamoxifen or AIs in the adjuvant treatment of postmenopausal women.</s><s>Large randomized trials have shown that initial treatment with AIs may reduce recurrence risk and improve survival compared with tamoxifen alone.</s><s>The Panel noted that tamoxifen alone is still appropriate for some patients.</s><s>Slightly more than half of the panelists believed that an AI should be used at some point during the course of adjuvant therapy.</s><s>Factors that favored the use of an AI include node positivity, high Ki67, high grade, lobular histology, and HER2 positivity.</s><s>In women at high risk of recurrence, the panel favored the use of an AI as initial therapy.</s><s>The Panel acknowledge that the importance of patient preference and tolerability of therapy, particularly given the modest differences between tamoxifen and AIs even in somewhat high-risk patients (Table <ref type="table" target="#tab_2">4</ref>) <ref type="bibr" target="#b35">[36,</ref><ref type="bibr" target="#b36">37]</ref>.</s></p><p><s>Over the past decade, multiple trials have examined the role of extended adjuvant endocrine therapy beyond 5 years of treatment.</s><s>Options include extended tamoxifen to 10 years, extended AI therapy to 10 years, or 5 years of tamoxifen and then switching to an AI.</s><s>The benefits of extended therapy include reductions in risk of loco-regional and distant recurrence and in contralateral breast cancer.</s><s>The Panel deliberated on which women should receive longer durations of therapy.</s><s>In general, the Panel recommended longer durations in women with moderate to high risk of recurrence, typically defined as stage II or III breast cancer.</s><s>In women with stage I cancers, the Panel favored only 5 years of treatment (Table <ref type="table" target="#tab_2">4</ref>).</s><s>Based on data from recently presented studies, the Panel was more inclined to recommend extended therapy in women who had received tamoxifen as initial therapy, and in women where secondary prevention was an important treatment goal <ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref>.</s><s>The Panel underscored the importance of patient preference and tolerability in this treatment decision, as extended therapy is associated with ongoing menopausal symptoms and risks to bone health, and yields only modest benefits in terms of preventing breast cancer recurrence, especially in patients who have completed 5 years of AI therapy (Table <ref type="table" target="#tab_2">4</ref>).</s></p><p><s>The Panel recommended that premenopausal women who are at high risk for recurrence and have concluded 5 years of tamoxifen should extend endocrine therapy for up to 10 years (Table <ref type="table" target="#tab_2">4</ref>) <ref type="bibr" target="#b34">[35]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Which patients should receive adjuvant chemotherapy? Triple-negative breast cancer</head><p><s>The Panel recommended adjuvant chemotherapy for triple-negative breast cancer (TNBC) stage T1b pN0 and higher; the majority recommended against routine adjuvant chemotherapy for pT1a pN0 TNBC (Table <ref type="table" target="#tab_2">4</ref>).</s><s>The Panel preferred anthracyclineand taxane-based chemotherapy for most patients, but particularly for those with stage II and III disease.</s><s>The Panel clearly recommended against routine use of platinum-based chemotherapy in unselected TNBC cases.</s><s>In BRCA1/2 associated cancers, the Panel was evenly split on whether to recommend adjuvant platinum chemotherapy though agreed that such patients should receive alkylating chemotherapy in addition to a taxane and anthracycline.</s><s>Acceptable regimens included dose-dense and non-dose-dense anthracycline-, taxane-, and alkylator chemotherapy schedules (Table <ref type="table" target="#tab_3">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HER2 positive breast cancer</head><p><s>The Panel recommended adjuvant chemotherapy and anti-HER2 therapy for HER2 positive, stage pT1b pN0 and higher breast cancers; it recommended against routine adjuvant chemotherapy and anti-HER2 therapy for pT1a pN0 HER2 positive breast cancers.</s><s>The Panel believed that the paclitaxel-trastuzumab regimen was sufficient for most stage 1, HER2 positive cancer but recommended anti-HER2 therapy be paired with additional chemotherapy agents for stage II or III cancer (Table <ref type="table" target="#tab_3">5</ref>).</s><s>The Panel recommended a duration of 1 year of adjuvant trastuzumab alone, based on current evidence (Table <ref type="table" target="#tab_3">5</ref>).</s><s>At the time of the Consensus Conference data of APHINITY trial were not available.</s><s>In women who received neoadjuvant anti-HER2 therapy with dual blockade pertuzumab and trastuzumab, the Panel recommended completion of one year of trastuzumab alone but did not recommend adjuvant pertuzumab based on current evidence.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Special article</head><p><s>The majority of the Panel endorsed adjuvant use of adequately evaluated biosimilar trastuzumab, according to the criteria of extrapolation defined between regulatory agencies.</s></p><p><s>There is evidence from a single randomized trial that extended adjuvant therapy with neratinib after 1 year of trastuzumab may reduce recurrence in HER2 positive breast cancer, particularly in ER positive, HER2 positive cancers.</s><s>The Panel did not specifically address the role of this agent pending further study (Table <ref type="table" target="#tab_3">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ER positive, HER2 negative breast cancer</head><p><s>Treatment decisions for chemotherapy in ER positive breast cancers can be guided by either IHC/pathology or by gene expression signatures.</s><s>The Panel identified traditional pathology factors as relative indications for adjuvant chemotherapy including nodepositive stage, extensive LVI, high Ki-67, and low hormonereceptor expression.</s><s>The role of young age, per se, as an indication for chemotherapy was less strongly endorsed given the growing appreciation for tumor biology as the determinant of outcome and the potential role for ovarian suppression.</s></p><p><s>The Panel recommended against adjuvant chemotherapy in women with stage 1 or 2, luminal-A-like cancers (strongly ER and PR positive, HER2 negative, with lower grade and proliferation markers), especially when genomic assays predicted the lack of benefit for chemotherapy treatment.</s><s>The Panel recommended against adjuvant chemotherapy in women with luminal-B-like tumors with low genomic risk scores on the 21-or 70-gene signatures, when presenting with limited nodal involvement <ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref>.</s><s>Some of the panelists urged caution about withholding adjuvant chemotherapy in node positive patients until more gene expression data in women treated with and without chemotherapy are available that will allow to safely de-escalate treatment in the ERþ/ HER2 negative, N1-3 subset.</s><s>In cases of intermediate genomic scores or greater, the Panel recommended chemotherapy in</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neoadjuvant therapy and post-neoadjuvant therapy</head><p><s>The Panel strongly endorsed the use of neoadjuvant therapy for stage II or III, HER2 positive or triple-negative breast cancer as the preferred initial treatment approach, particularly when there is any suggestion that treatment response might enable deescalation of surgery or radiotherapy.</s><s>For HER2 positive cancers, the Panel endorsed dual anti-HER2 neoadjuvant therapy with pertuzumab and trastuzumab with chemotherapy as a commonly administered option.</s><s>For triple-negative cancers, the Panel recommended similar approaches to those that would be used in adjuvant therapy (Table <ref type="table" target="#tab_3">5</ref>).</s></p><p><s>Patients with residual cancer after neoadjuvant chemotherapy are at greater risk for recurrence than those who achieve complete pathologic response.</s><s>At this juncture, there are no published data that additional therapy-beyond 'standard' treatment-reduces recurrence risk in women with residual disease <ref type="bibr" target="#b41">[42]</ref>.</s><s>The Panel was ambivalent about the role of additional therapy in the postneoadjuvant setting, and there was no consensus on whether additional therapy should routinely be added, or which treatment might be preferred.</s><s>A recent trial used capecitabine in this setting with very encouraging results, but the panelists noted the absence of confirmatory data and the historical lack of substancial benefit for adjuvant capecitabine.</s><s>Ongoing clinical trials are evaluating the role of therapeutic escalation with various treatments including additional chemotherapies, targeted agents, anti-HER2 therapies, PARP inhibitors, and immune checkpoint inhibitors in this setting.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjuvant use of bone modifying therapy</head><p><s>Based on a meta-analysis of multiple trials, the Panel strongly endorsed the use of bisphosphonates as adjuvant treatment of postmenopausal women with breast cancer <ref type="bibr" target="#b42">[43,</ref><ref type="bibr" target="#b88">87]</ref>.</s><s>Preferred regimens include zoledronic acid every 6 months for 5 years, or daily oral clodronate for 3 years.</s><s>The Panel recommended against such treatments for premenopausal women who are continuing to have regular menstrual cycles.</s><s>However, a majority of the Panel favored this option for premenopausal women receiving OFS.</s><s>Denosumab has been shown to reduce bone-health related events in breast cancer patients and may reduce recurrence but only a minority of panelists favored the option of substituting denosumab for bisphosphonates <ref type="bibr" target="#b42">[43,</ref><ref type="bibr" target="#b44">44]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survivorship and quality of life</head><p><s>The Panel endorsed scalp cooling devices to reduce the likelihood of alopecia related to neo/adjuvant chemotherapy with nonanthracycline regimens <ref type="bibr" target="#b45">[45]</ref>.</s></p><p><s>The Panel endorsed lifestyle, diet, and weight management strategies appropriate to the general population, acknowledging that there are as yet no data that specific diet, lifestyle, or weight interventions affect the risk of breast cancer recurrence.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Considerations in special populations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Elderly patients</head><p><s>The Panel resolutely endorsed the statement that there is no absolute age limit for adjuvant chemotherapy but rather the recommendation should depend on the health status of the patient, the risk of cancer recurrence, the likely benefit of therapy, and patient preferences.</s><s>The Panel acknowledged that many older patients (greater than age 65 years) with ER positive, HER2 negative, low clinical and/or genomic risk and taking adjuvant endocrine therapy could omit radiation therapy after breast conserving surgery, particularly those with multiple comorbid health conditions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pregnancy after breast cancer</head><p><s>There are few data to guide the optimal timing of pregnancy after breast cancer, and this is an important area of ongoing research.</s><s>Given the known benefits of adjuvant endocrine therapy, panelists generally favored an approach that involved 18-24 months of treatment with endocrine before pregnancy, and reiterated the importance of resuming endocrine treatment after pregnancy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Male breast cancer</head><p><s>The vast majority of male breast cancers are ER positive.</s><s>The Panel recommended that men with ER positive tumors should receive adjuvant tamoxifen.</s><s>For men with true contraindications to tamoxifen, the Panel believed GnRH agonist therapy and an AI could be an alternative.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Testing for hereditary breast cancer</head><p><s>The Panel endorsed genetic testing of BRCA-1 and BRCA-2 for patients with strong family history of breast cancer regardless of age; for women diagnosed at age 40 years regardless of tumor subtype, or for women with triple-negative breast cancer age 60 years.</s><s>Germline multigene panel testing may be offered to patients who meet criteria for hereditary cancer syndromes, including breast and ovarian or Lynch syndrome; and is particularly appropriate in cases of early-onset breast cancer or in women with strong family history of breast cancer when BRCA1/ 2 testing has been uninformative.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>The conference endorsed recent trial evidence supporting areas of 'escalation' or 'de-escalation' of local and systemic therapies.</s><s>A large number of treatment recommendations are shown although a significant variation in the level of agreement was noted.</s><s>In fact, among more than 200 questions, only a few statements (radiation in 4 or more positive nodes, distinction between luminal A-and luminal B-like in order to identify important clinical categories) resulted in 100% concordance.</s><s>The large variation in the degrees of support is reflected in the votes recorded in supplementary Appendix S1, available at Annals of Oncology online.</s><s>The Panel recognized that recommendations are not intended for all patients, but rather for the majority of them in common clinical situations.</s><s>Fine-tuning of adjuvant therapies for the patient of today implies that the available treatments need to be adjusted to the patient's tumor characteristics, co-morbidities, economic constraints and acceptance of therapies.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Treatment recommendations for loco-regional therapy</s></p></div></figDesc><table><row><cell>Local therapy</cell><cell>Theme</cell><cell>De-escalation</cell><cell>Escalation</cell></row><row><cell>Primary surgery: invasive</cell><cell>Margins</cell><cell>Re-excision and mastectomies can be</cell><cell>Re-excision for larger margins discour-</cell></row><row><cell>breast cancer</cell><cell></cell><cell>avoided with margins no larger than</cell><cell>aged including cases with aggres-</cell></row><row><cell></cell><cell></cell><cell>no tumor on ink</cell><cell>sive biology</cell></row><row><cell></cell><cell>Multifocal and multicentric disease</cell><cell>Breast conservation if margins clear and</cell><cell>Mastectomy in other cases</cell></row><row><cell></cell><cell></cell><cell>RT anticipated</cell><cell></cell></row><row><cell>Surgery for DCIS</cell><cell>Margins</cell><cell>2 mm margins sufficient to avoid second</cell><cell>Re-excision for larger margins</cell></row><row><cell></cell><cell></cell><cell>surgery</cell><cell>discouraged</cell></row><row><cell>Surgery after neoadjuvant</cell><cell>Surgery of the breast</cell><cell>Resection of residual disease and not ori-</cell><cell>Resection of the original tumor area in</cell></row><row><cell>chemotherapy in case of</cell><cell></cell><cell>ginal tumor area</cell><cell>cases of refractory disease</cell></row><row><cell>downstaging in breast</cell><cell>Margins</cell><cell>No tumor on ink in concentric shrinkage/</cell><cell>Consider re-excision (2 mm margins) in</cell></row><row><cell>and axilla</cell><cell></cell><cell>unifocal residual disease</cell><cell>multifocal residual disease/'scat-</cell></row><row><cell></cell><cell></cell><cell></cell><cell>tered' remission</cell></row><row><cell></cell><cell>Sentinel lymph node biopsy in cN (À)</cell><cell>Appropriate in most cases</cell><cell>Axillary dissection if sentinel lymph</cell></row><row><cell></cell><cell>at diagnosis</cell><cell></cell><cell>node metastasis detected</cell></row><row><cell></cell><cell>Sentinel lymph node biopsy in cN (þ)</cell><cell>Appropriate only if three or more lymph</cell><cell>Axillary dissection in most cases out-</cell></row><row><cell></cell><cell>at diagnosis</cell><cell>nodes detected as sentinels</cell><cell>side of clinical trials</cell></row><row><cell>Radiotherapy</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Hypofractionation</cell><cell>Strong recommendation for ages !50</cell><cell>Consider standard radiotherapy regi-</cell></row><row><cell></cell><cell></cell><cell>and node negative</cell><cell>mens for all others</cell></row><row><cell></cell><cell>Partial breast irradiation</cell><cell>Consider for ASTRO/ESTRO low risk</cell><cell>Consider whole breast irradiation for all</cell></row><row><cell></cell><cell></cell><cell>group, especially when receiving adju-</cell><cell>others</cell></row><row><cell></cell><cell></cell><cell>vant endocrine therapy</cell><cell></cell></row><row><cell></cell><cell>Boost</cell><cell>Omit boost in patients !60 years, low</cell><cell>Consider boost in other patients</cell></row><row><cell></cell><cell></cell><cell>grade, or favorable biological profile</cell><cell></cell></row><row><cell></cell><cell>Post-mastectomy radiation</cell><cell>Consider omitting radiotherapy in</cell><cell>PMRT in patients with pT3 or four or</cell></row><row><cell></cell><cell>therapy (PMRT)</cell><cell>women with pT1-pT2, pN1 (1-3), and</cell><cell>more positive lymph nodes</cell></row><row><cell></cell><cell></cell><cell>favorable biological profile</cell><cell></cell></row><row><cell></cell><cell>Regional nodal irradiation (RNI)</cell><cell>Consider omitting RNI in N1 (1-3 positive</cell><cell>RNI in N1 cancers and adverse clinical</cell></row><row><cell></cell><cell></cell><cell>lymph nodes) in the absence of ad-</cell><cell>features ( 40 years, low or negative</cell></row><row><cell></cell><cell></cell><cell>verse clinical factors</cell><cell>estrogen receptor (ER), G3, extensive</cell></row><row><cell></cell><cell></cell><cell></cell><cell>lympho-vascular invasion) or &gt; 3</cell></row><row><cell></cell><cell></cell><cell></cell><cell>positive nodes</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Definition of subtypes</s></p></div></figDesc><table><row><cell>Clinical grouping</cell></row></table><note><p><s>a Basal like breast cancer and HER2-enriched subtype can be defined by genomic assay only.bNo</s><s>role for gene testing in clinical pathologic low risk cases (pT1a, pT1b, G1, ER high, pN0).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>(Neo)-Adjuvant systemic treatment recommendations for ER positive/HER2 negative early breast cancer</s></p></div></figDesc><table><row><cell>Subtypes according to clinical-pathologi-</cell><cell>Treatment recommendation</cell><cell>De-escalation</cell><cell>Escalation</cell></row><row><cell>cal and genomic risk assessment</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">ER positive &amp; HER2-negative</cell><cell></cell></row><row><cell>High receptor, low tumour burden (pT1a,</cell><cell>Endocrine therapy alone accord-</cell><cell></cell><cell></cell></row><row><cell>pT1b), no nodal involvement (pN0), low</cell><cell>ing to menopausal status</cell><cell></cell><cell></cell></row><row><cell>proliferation, low grade or low "genomic</cell><cell></cell><cell></cell><cell></cell></row><row><cell>risk"</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Premenopausal</cell><cell>Tamoxifen 5 years</cell><cell>No role for extended adjuvant</cell><cell></cell></row><row><cell></cell><cell></cell><cell>tamoxifen beyond 5 years No</cell><cell></cell></row><row><cell></cell><cell></cell><cell>OFS</cell><cell></cell></row><row><cell>Postmenopausal</cell><cell>Tamoxifen or AI for 5 years</cell><cell>The majority of the panel recom-</cell><cell></cell></row><row><cell></cell><cell></cell><cell>mended against extended</cell><cell></cell></row><row><cell></cell><cell></cell><cell>adjuvant endocrine therapy</cell><cell></cell></row><row><cell></cell><cell></cell><cell>beyond 5 years</cell><cell></cell></row><row><cell>High/Intermediate degree of ER and PgR</cell><cell>Endocrine therapy according</cell><cell></cell><cell></cell></row><row><cell>expression, intermediate tumour burden</cell><cell>to menopausal status plus</cell><cell></cell><cell></cell></row><row><cell>pT1c, pT2, pN0 or pN1 (1-3), intermediate</cell><cell>adjuvant chemotherapy</cell><cell></cell><cell></cell></row><row><cell>or high proliferation or grade, and/or inter-</cell><cell></cell><cell></cell><cell></cell></row><row><cell>mediate "genomic risk"</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Premenopausal</cell><cell>OFS plus tamoxifen or OFS plus</cell><cell></cell><cell>Consider addition of chemother-</cell></row><row><cell>Uncertain "clinical risk" (node negative)</cell><cell>exemestane</cell><cell></cell><cell>apy in selected cases</cell></row><row><cell>"intermediate genomic risk"</cell><cell></cell><cell></cell><cell>Extended adjuvant endocrine</cell></row><row><cell></cell><cell></cell><cell></cell><cell>therapy with tamoxifen in some</cell></row><row><cell></cell><cell></cell><cell></cell><cell>cases</cell></row><row><cell>Premenopausal intermediate/high</cell><cell>OFS plus exemestane plus adju-</cell><cell></cell><cell>Chemotherapy</cell></row><row><cell>"clinical risk" (node positive)</cell><cell>vant chemotherapy in many</cell><cell></cell><cell>Extended adjuvant endocrine</cell></row><row><cell>"intermediate/high genomic risk"</cell><cell>cases</cell><cell></cell><cell>therapy with tamoxifen</cell></row><row><cell>Post-menopausal</cell><cell>AI up front</cell><cell></cell><cell>Bisphosphonates</cell></row><row><cell>Uncertain "clinical risk" (node negative)</cell><cell>Chemotherapy in many cases</cell><cell></cell><cell></cell></row><row><cell>"intermediate genomic risk"</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Postmenopausal "intermediate/high</cell><cell>Chemotherapy</cell><cell></cell><cell>Extended adjuvant AI according</cell></row><row><cell>genomic risk" and intermediate/high</cell><cell>AI as first endocrine therapy for at</cell><cell></cell><cell>to risk and tolerability</cell></row><row><cell>"clinical risk" (node positive)</cell><cell>least 3-5 years</cell><cell></cell><cell>Bisphosphonates</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Denosumab has been shown to</cell></row><row><cell></cell><cell></cell><cell></cell><cell>reduce bone-health related</cell></row><row><cell></cell><cell></cell><cell></cell><cell>events in breast cancer patients</cell></row><row><cell>Intermediate to low ER and PR expression</cell><cell>Adjuvant chemotherapy plus</cell><cell></cell><cell></cell></row><row><cell>Higher tumor burden (typically T3 and/or N2-3)</cell><cell>endocrine therapy according</cell><cell></cell><cell></cell></row><row><cell>More proliferative / higher Ki67</cell><cell>to menopausal status</cell><cell></cell><cell></cell></row><row><cell>"Intermediate to high genomic risk markers"</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Premenopausal high risk</cell><cell>Adjuvant chemotherapy and OFS</cell><cell></cell><cell>Extended adjuvant AI accord-</cell></row><row><cell></cell><cell>þ AI (if premenopausal after</cell><cell></cell><cell>ing to risk and tolerability</cell></row><row><cell></cell><cell>chemo)</cell><cell></cell><cell></cell></row><row><cell>Postmenopausal high risk</cell><cell>Adjuvant chemotherapy and AI</cell><cell></cell><cell>Extended adjuvant AI according</cell></row><row><cell></cell><cell></cell><cell></cell><cell>to risk and tolerability</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Bisphosphonates</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Denosumab has been shown to</cell></row><row><cell></cell><cell></cell><cell></cell><cell>reduce bone-health related</cell></row><row><cell></cell><cell></cell><cell></cell><cell>events in breast cancer patients</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 5 .</head><label>5</label><figDesc><div><p><s>Adjuvant systemic treatment recommendations for triple negative and HER2 positive early breast cancer</s></p></div></figDesc><table><row><cell cols="2">Special article</cell><cell></cell><cell></cell></row><row><cell>Subtypes according to</cell><cell>Treatment recommendation</cell><cell>De-escalation</cell><cell>Escalation</cell></row><row><cell>clinical-pathologic and</cell><cell></cell><cell></cell><cell></cell></row><row><cell>genomic risk assessment</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ductal triple negative</cell><cell></cell><cell></cell><cell></cell></row><row><cell>pT1a node negative</cell><cell></cell><cell>No routine adjuvant chemo-</cell><cell></cell></row><row><cell></cell><cell></cell><cell>therapy for stage pT1a pN0.</cell><cell></cell></row><row><cell>Higher T and N stage</cell><cell>Neoadjuvant therapy for stage II or III</cell><cell>Dose-dense adjuvant chemo-</cell><cell>No consensus on post-neoadjuvant treatment in</cell></row><row><cell></cell><cell>is suggested as initial treatment</cell><cell>therapy preferred by only a</cell><cell>case of residual disease.</cell></row><row><cell></cell><cell>approach.</cell><cell>minority of the consensus</cell><cell>In BRCA1/2 associated cancers, the Panel was</cell></row><row><cell></cell><cell>Chemotherapy should include</cell><cell>panel</cell><cell>evenly split on whether to recommend (neo)ad-</cell></row><row><cell></cell><cell>anthracycline and taxanes</cell><cell></cell><cell>juvant platinum chemotherapy though agreed</cell></row><row><cell></cell><cell></cell><cell></cell><cell>that such patients should receive alkylating</cell></row><row><cell></cell><cell></cell><cell></cell><cell>chemotherapy.</cell></row><row><cell>ER negative &amp; HER2-positive</cell><cell></cell><cell></cell><cell></cell></row><row><cell>pT1a node negative</cell><cell>No systemic therapy</cell><cell>No systemic therapy</cell><cell></cell></row><row><cell>pT1 b,c node negative</cell><cell>Chemotherapy plus trastuzumab</cell><cell>Consider paclitaxel plus 1 year</cell><cell>Dual blockade with pertuzumab and trastuzu-</cell></row><row><cell></cell><cell></cell><cell>trastuzumab without</cell><cell>mab improves outcome among patients who</cell></row><row><cell></cell><cell></cell><cell>anthracyclines</cell><cell>are at higher risk for relapse because of</cell></row><row><cell></cell><cell></cell><cell></cell><cell>lymph-node involvement or hormone-recep-</cell></row><row><cell></cell><cell></cell><cell></cell><cell>tor negativity [90] a</cell></row><row><cell>Higher T or N stage</cell><cell>Neoadjuvant therapy for stage II or III</cell><cell>Patients may be treated with</cell><cell>Dual anti-HER2 therapy with pertuzumab and tras-</cell></row><row><cell></cell><cell>is the preferred initial treatment</cell><cell>TCH regimen</cell><cell>tuzumab with chemotherapy as the preferred</cell></row><row><cell></cell><cell>approach.</cell><cell></cell><cell>option in the neoadjuvant setting</cell></row><row><cell></cell><cell>Anthracycline followed by taxane</cell><cell></cell><cell>Dual blockade with pertuzumab and trastuzumab</cell></row><row><cell></cell><cell>with concurrent trastuzumab con-</cell><cell></cell><cell>improves outcome among patients who are at</cell></row><row><cell></cell><cell>tinued to 12 months</cell><cell></cell><cell>higher risk for relapse because of lymph-node in-</cell></row><row><cell></cell><cell></cell><cell></cell><cell>volvement or hormone-receptor negativity [90] a</cell></row><row><cell>ER positive and</cell><cell>As above plus endocrine therapy ap-</cell><cell></cell><cell>Extended adjuvant therapy with neratinib after</cell></row><row><cell>HER2-positive</cell><cell>propriate to menopausal status</cell><cell></cell><cell>1 year of trastuzumab may reduce recurrence</cell></row><row><cell></cell><cell></cell><cell></cell><cell>in ER positive subgroup a</cell></row></table><note><p><s>a The Panel did not answer the question on dual blockade in the adjuvant setting since data on APHINITY trial were not available.</s><s>The Panel did not answer the question on extended adjuvant therapy with neratinib.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1712">| Curigliano et al. Volume 28 | Issue 8 | 2017</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We gratefully thank all participants of the 15th St. Gallen International Breast Cancer Conference for their many useful suggestions.</s><s>In addition to Panel members, we also thank Carmen Criscitiello, European Institute of Oncology, Milano and Michael Knauer, Kantonsspital, St. Gallen, for their substantial assistance in the collection of voting results.</s><s>In recognition of their outstanding contribution as longstanding coauthors of several former St. Gallen consensus manuscripts, we especially want to thank Aron Goldhirsch, Alan Coates and Richard Gelber for their legacy and for their fundamental support of the conference-development and its consensus manuscript during the last 30 years.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>None declared.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure</head><p><s>Conflict of interest statements from all presenters and Panel members were available on-line during the conference and are listed in supplementary Appendix S1, available at Annals of Oncology online.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Ductal carcinoma in situ of the breast</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Burstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Polyak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Wong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page" from="1430" to="1441" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Long-term outcome of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP-17 and B-24 randomized clinical trials for DCIS</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">L</forename><surname>Wapnir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Dignam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Fisher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="478" to="488" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ</title>
		<author>
			<persName><forename type="first">M</forename><surname>Morrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Van Zee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Solin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="4040" to="4046" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Forbes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sestak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Howell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="866" to="873" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, doubleblind, phase 3 clinical trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Margolese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Cecchini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Julian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="849" to="856" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Moran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Schnitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Giuliano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1507" to="1515" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review</title>
		<author>
			<persName><forename type="first">L</forename><surname>De La Cruz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Moody</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Tappy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="3241" to="3249" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Giuliano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Ballman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">305</biblScope>
			<biblScope unit="page" from="569" to="575" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy</title>
		<author>
			<persName><forename type="first">B</forename><surname>Ataseven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lederer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">U</forename><surname>Blohmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1118" to="1127" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Neoadjuvant chemotherapy is not a contraindication for nipple sparing mastectomy</title>
		<author>
			<persName><forename type="first">S</forename><surname>Santoro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Loreti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cavaliere</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="661" to="666" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kuehn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bauerfeind</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fehm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="609" to="618" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Boughey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Suman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Mittendorf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1455" to="1461" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Boileau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Poirier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Basik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="258" to="264" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mamtani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Barrio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>King</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="3467" to="3474" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients</title>
		<author>
			<persName><forename type="first">H</forename><surname>El Hage Chehade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Headon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">El</forename><surname>Tokhy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg</title>
		<imprint>
			<biblScope unit="volume">212</biblScope>
			<biblScope unit="page" from="969" to="981" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Long-term results of hypofractionated radiation therapy for breast cancer</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Whelan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pignol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Levine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="513" to="520" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement</title>
		<author>
			<persName><forename type="first">C</forename><surname>Correa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Leonardi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pract Rad Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="73" to="79" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial</title>
		<author>
			<persName><forename type="first">H</forename><surname>Bartelink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Maingon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Poortmans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="47" to="56" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC boost vs no boost trial: a randomized clinical trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Vrieling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Werkhoven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Maingon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Oncol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="42" to="48" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">20 Study Investigators. Regional nodal irradiation in early-stage breast cancer</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Whelan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">A</forename><surname>Olivotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Parulekar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="307" to="316" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">EORTC Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular irradiation in breast cancer</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Poortmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Collette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kirkove</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="317" to="327" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">N</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ismaila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1134" to="1150" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Prospective validation of a 21-gene expression assay in breast cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Sparano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Makower</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="2005" to="2014" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment</title>
		<author>
			<persName><forename type="first">O</forename><surname>Gluz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">A</forename><surname>Nitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Christgen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="2341" to="2349" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">MINDACT Investigators. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer</title>
		<author>
			<persName><forename type="first">F</forename><surname>Cardoso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Veer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bogaerts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="717" to="729" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gnant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Filipits</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Greil</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="339" to="345" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">EP Investigators. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors</title>
		<author>
			<persName><forename type="first">M</forename><surname>Filipits</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rudas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jakesz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="6012" to="6020" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gnant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sestak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Filipits</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1685" to="1691" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Comparisons between different polychemotherapy regimens for early breast cancer: metaanalyses of long-term outcome among 100,000 women in 123 randomized trials</title>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">379</biblScope>
			<biblScope unit="page" from="432" to="444" />
			<date type="published" when="2012">2012</date>
		</imprint>
		<respStmt>
			<orgName>Early Breast Cancer Trialists Collaborative Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Sgroi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sestak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cuzick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1067" to="1076" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">The EndoPredict score provides prognostic information on late distant metastases in ERþ/HER2-breast cancer patients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Dubsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Brase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jakesz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2959" to="2964" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Adjuvant ovarian suppression in premenopausal breast cancer</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Francis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Regan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Fleming</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="436" to="446" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Adjuvant exemestane with ovarian suppression in premenopausal breast cancer</title>
		<author>
			<persName><forename type="first">O</forename><surname>Pagani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Regan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Walley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="107" to="118" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gnant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mlineritsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Stoeger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="313" to="320" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of clinical oncology clinical practice guideline focused update</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Burstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Temin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="2255" to="2269" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dowsett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Forbes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">386</biblScope>
			<biblScope unit="page" from="1341" to="1352" />
			<date type="published" when="2015">2015. 10001</date>
		</imprint>
		<respStmt>
			<orgName>Early Breast Cancer Trialists&apos; Collaborative Group (EBCTCG</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Relative effectiveness of letrozole compared With tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial</title>
		<author>
			<persName><forename type="first">O</forename><surname>Metzger Filho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Giobbie-Hurder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mallon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="2772" to="2779" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Extending aromatase-inhibitor adjuvant therapy to 10 years</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Goss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Ingle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">I</forename><surname>Pritchard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="209" to="219" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Tjan-Heijnen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Van Hellemond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Peer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">San Antonio Breast Cancer Symposium</title>
				<meeting><address><addrLine>San Antonio, TX</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2016-12-10">2016, 6-10 December 2016</date>
			<biblScope unit="page" from="S1" to="03" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Blok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cjh</forename><surname>Van De Velde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Meershoek-Klein</forename><surname>Kranenbarg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">San Antonio Breast Cancer Symposium</title>
				<meeting><address><addrLine>San Antonio, TX</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2016-12-10">2016, 6-10 December 2016</date>
			<biblScope unit="page" from="S1" to="04" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">A randomized, doubleblinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (þ) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42. San Antonio Breast Cancer Symposium</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Mamounas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bandos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Lembersky</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016-12-06">2016. 2016 Dec 6-10</date>
			<biblScope unit="page" from="S1" to="05" />
			<pubPlace>San Antonio, TX</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Adjuvant capecitabine for breast cancer after preoperative chemotherapy</title>
		<author>
			<persName><forename type="first">N</forename><surname>Masuda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ohtani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="2147" to="2159" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials</title>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">386</biblScope>
			<biblScope unit="page" from="1353" to="1361" />
			<date type="published" when="2015">2015. 10001</date>
		</imprint>
		<respStmt>
			<orgName>Early Breast Cancer Trialists&apos; Collaborative Group (EBCTCG</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Erratum Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page">30</biblScope>
			<date type="published" when="2016">2016. 10013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gnant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pfeiler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Dubsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">386</biblScope>
			<biblScope unit="page" from="433" to="443" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Nangia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Niravath</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">San Antonio Breast Cancer Symposium</title>
				<meeting><address><addrLine>San Antonio, TX</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2016-12-10">2016, 6-10 December 2016</date>
			<biblScope unit="page" from="S5" to="7" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Clinical evaluation of a multiplegene sequencing panel for hereditary cancer risk assessment</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Kurian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Hare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Mills</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="2001" to="2009" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<monogr>
		<title level="m" type="main">Groupe Europe ´en de Curiethe ´rapie of European Society for Radiotherapy and Oncology</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strnad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">J</forename><surname>Ott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hildebrandt</surname></persName>
		</author>
		<imprint>
			<publisher>GEC-ESTRO</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial</title>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="229" to="238" />
			<date type="published" when="2016">2016. 10015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Sikov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Berry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Perou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="13" to="21" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Adaptive randomization of veliparib-carboplatin treatment in breast cancer</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Rugo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">I</forename><surname>Olopade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Demichele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="23" to="34" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>I-SPY 2 Investigators</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Arbeitsgemeinschaft Gyn€ akologische Onkologie-Breast (AGO-B) Investigators. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Untch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jackisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schneeweiss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">German Breast Group (GBG)</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="345" to="356" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>Lancet Oncol</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: a MICHELANGO study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Gianni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mansutti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anton</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page">502</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial</title>
		<author>
			<persName><forename type="first">L</forename><surname>Gianni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pienkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Im</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="791" to="800" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) þ pertuzumab (P) vs docetaxel þ carboplatin þ trastuzumab þ P (TCHP) treatment in patients with HER2-positive (HER2þ) early breast cancer (EBC) (KRISTINE)</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Hurvitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Symmans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page">500</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">I-SPY 2 Investigators. Adaptive randomization of neratinib in early breast cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yee</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="11" to="22" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Curigliano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Meric-Bernstam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="191" to="198" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">NeoPalAna: neoadjuvant palbociclib, a cyclindependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">X</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Luo</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.CCR-16-3206</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<date type="published" when="2016">2017. 2016</date>
		</imprint>
	</monogr>
	<note>epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Interim results from neoMONARCH: a neoadjuvant phase II study of abemaciclib in postmenopausal women with HR þ/HER2-breast cancer (BC)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hurvitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Abad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rostorfor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">suppl_6</biblScope>
			<biblScope unit="page">A13</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: a multicenter trial</title>
		<author>
			<persName><forename type="first">Hdd</forename><surname>Bear</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Robidoux</surname></persName>
		</author>
		<idno>P2-10-04</idno>
	</analytic>
	<monogr>
		<title level="m">San Antonio Breast Cancer Symposium</title>
				<meeting><address><addrLine>San Antonio, TX</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2016-12-10">2016, 6-10 December 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel þ cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Blum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Flyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yothers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>suppl; abstr 1000</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer</title>
		<author>
			<persName><forename type="first">R</forename><surname>Bell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Parmar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="754" to="760" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial</title>
		<author>
			<persName><forename type="first">H</forename><surname>Joensuu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Kellokumpu-Lehtinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Huovinen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Oncol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="793" to="800" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2Â2 factorial, randomised phase 3 trial</title>
		<author>
			<persName><forename type="first">Del</forename><surname>Mastro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Placido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bruzzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">385</biblScope>
			<biblScope unit="issue">9980</biblScope>
			<biblScope unit="page" from="1863" to="1872" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial</title>
		<author>
			<persName><forename type="first">T</forename><surname>Foukakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Von Minckwitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">O</forename><surname>Bengtsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">316</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="1888" to="1896" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Piccart-Gebhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Holmes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Baselga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1034" to="1042" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled</title>
		<author>
			<persName><forename type="first">A</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Delaloge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Holmes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="367" to="377" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Van Ramshorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Der Heiden-Van Der Loo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Dackus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res Treat</title>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">393</biblScope>
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
	<note>Breast Cancer Res Treat</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Tolaney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Barry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Dang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="134" to="141" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ribi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bernhard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1601" to="1610" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized phase III femara versus anastrozole clinical evaluation (FACE) trial</title>
		<author>
			<persName><forename type="first">I</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yardley</forename><forename type="middle">D</forename><surname>Burris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1041" to="1048" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Rugo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Melin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">317</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="606" to="614" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG S1202)</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Henry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Unger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Schott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">San Antonio Breast Cancer Symposium</title>
				<meeting><address><addrLine>San Antonio, TX</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2016-12-10">2016, 6-10 December 2016</date>
			<biblScope unit="page" from="S5" to="06" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Nanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Q</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Dees</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="2460" to="2467" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Y</forename><surname>Dirix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Takacs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Nikolinakos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">San Antonio Breast Cancer Symposium</title>
				<meeting><address><addrLine>San Antonio, TX</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2015-12-12">2015, 8-12 December 2015</date>
			<biblScope unit="page" from="S1" to="04" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Diamond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Hamilton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>suppl; abstr 1009</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Palbociclib and letrozole in advanced breast cancer</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Finn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Rugo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="1925" to="1936" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">´f</forename><surname>Andre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="209" to="219" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Ribociclib as first-line therapy for HR-positive, advanced breast cancer</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Hortobagyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Stemmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Burris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="1738" to="1748" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Barrios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Eiermann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="141" to="148" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">PHEREXA: a phase III study of trastuzumab (H) þ capecitabine (X) 6 pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting</title>
		<author>
			<persName><forename type="first">A</forename><surname>Urruticoechea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rizwanullah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Im</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>suppl): abstr 504</note>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Primary analysis of PERTAIN: a randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer</title>
		<author>
			<persName><forename type="first">G</forename><surname>Arpino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-M</forename><surname>Ferrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>De La Haba-Rodriguez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">San Antonio Breast Cancer Symposium</title>
				<meeting><address><addrLine>San Antonio, TX</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2016-12-10">2016, 6-10 December 2016</date>
			<biblScope unit="page" from="S3" to="04" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Fribbens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>O'leary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kilburn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="2961" to="2968" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">TNT: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tutt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kilburn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">San Antonio Breast Cancer Symposium</title>
				<meeting><address><addrLine>San Antonio, TX</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2014-09-13">2014, 9-13 December 2014</date>
			<biblScope unit="page" from="S3" to="4" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of VþTMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)þC/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer</title>
		<author>
			<persName><forename type="first">V</forename><surname>Die ´ras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mee</forename><surname>Robson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">San Antonio Breast Cancer Symposium</title>
				<meeting><address><addrLine>San Antonio, TX</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2016-12-10">2016, 6-10 December 2016</date>
		</imprint>
	</monogr>
	<note>abstr P4-22-02</note>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HRþ/ HER2-advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Baselga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S-A</forename><surname>Im</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Iwata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">San Antonio Breast Cancer Symposium</title>
		<imprint>
			<biblScope unit="page" from="S6" to="7" />
			<date type="published" when="2015-12-12">2015, 8-12 December 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">BELLE-3: A phase III study of buparlisibþfulvestrant in postmenopausal women with HRþ, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment</title>
		<author>
			<persName><forename type="first">Di</forename><surname>Leo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Seok</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ciruelos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">San Antonio Breast Cancer Symposium</title>
				<meeting><address><addrLine>San Antonio, TX</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2016-12-10">2016, 6-10 December 2016</date>
			<biblScope unit="page" from="S4" to="07" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Pictilisib for oestrogen receptorpositive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Krop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">A</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ganju</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="811" to="821" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Endocrine therapy plus zoledronic acid in premenopausal breast cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gnant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mlineritsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Schippinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">360</biblScope>
			<biblScope unit="page" from="679" to="691" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">An international study to increase concordance in Ki67 scoring</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Polley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mod Pathol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="778" to="786" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">An international ki67 reproducibility study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Polley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="1897" to="1906" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer</title>
		<author>
			<persName><forename type="first">G</forename><surname>Von Minckwitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Procter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>De Azambuja</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="122" to="131" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
